K. KumarSankhalaMD
Oncology • Beverly Hills, CAGynecologic Cancer, Sarcoma, Thoracic Cancer
Advanced Cancers and Sarcoma Medical Oncology Clinical Research and Experimental Therapuitics
Dr. Sankhala is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9100 Wilshire Blvd Ste 840w
Beverly Hills, CA 90212Phone+1 310-908-0057Fax+1 844-662-6772
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 2010 - 2012- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2010
Dr. S.N. Medical CollegeClass of 1997, MBBS
U Texas HSC- Institute for Drug Development
Certifications & Licensure
TX State Medical License 2011 - 2026
CA State Medical License 2011 - 2025- American Board of Internal Medicine Medical Oncology
- American Board of Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- AACR-NCI Scholarship for “Molecular Biology in Clinical Oncology” workshop AACR-NCI, 2007
- The American Society of Clinical Oncology Foundation Merit Award ASCO, 2005
Clinical Trials
- Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor Start of enrollment: 2015 Jun 01
Publications & Presentations
PubMed
- 34 citationsPhase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Staal Rohrberg, Sant P. Chawla
Clinical Cancer Research. 2021-02-23 - 86 citationsPhase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid TumorsAlain C. Mita, Chris H. Takimoto, Monica M. Mita, Anthony W. Tolcher, Kamalesh Kumar Sankhala
Clinical Cancer Research. 2010-06-01 - 193 citationsPhase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue SarcomasSant P. Chawla, Arthur P. Staddon, Laurence H. Baker, Scott M. Schuetze, Anthony W. Tolcher
Journal of Clinical Oncology. 2012-01-01
Committees
- Board Member, Institutional Review Board (IRB) 2018 - 2020
- Board Member, Disease Research Group 2017 - 2020
- Board Member, Protocol Review and Monitoring Committee 2017 - 2018
- Member, Pharmacy Utilization Management Committee 2011 - 2013
Professional Memberships
- Member
Other Languages
- Hindi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
